Introduction {#section1-1758835920937902}
============

Immune checkpoint inhibitors (ICIs) have altered the treatment landscape for advanced lung cancer since their initial approval in patients with pre-treated advanced non-small cell lung carcinoma (NSCLC). They are now standard of care, either in combination or as monotherapy, in advanced non-oncogene-driven NSCLC, extensive stage small cell carcinoma in combination with chemotherapy and as a consolidation therapy in unresectable stage III NSCLC. However, responses to ICI therapy are not ubiquitous, with many patients displaying primary, also known as innate, resistance to ICI monotherapy. In addition, a number of patients who derive an initial clinical benefit from ICI will subsequently experience systemic disease progression, exhibiting secondary or acquired resistance. In this paper, we review the definition and clinical characteristics of resistance, provide an overview on biomarkers of such resistance, as well as systemic treatment approaches in patients with NSCLC in the first-line setting and in patients who have progressed after prior exposure to immunotherapy. The role of treatment beyond progression for patients with slow progression and/or mixed treatment response with clinical benefit,^[@bibr1-1758835920937902][@bibr2-1758835920937902]--[@bibr3-1758835920937902]^ and the use of local therapy (surgery, stereotactic body radiation therapy and radio-frequency ablation) for oligo-progression^[@bibr4-1758835920937902]^ are beyond the scope of this article and has been discussed in other reviews.^[@bibr5-1758835920937902][@bibr6-1758835920937902]--[@bibr7-1758835920937902]^

The immune response and ICI therapy {#section2-1758835920937902}
===================================

The generation of an anti-tumor immune response relies on a cyclical process of events elegantly described as the cancer immunity cycle.^[@bibr8-1758835920937902]^ Initially, tumor cell death leads to the release of antigens, which are captured by dendritic cells (DCs) and antigen-presenting cells (APCs). Next, APCs present captured antigens *via* the major histocompatibility complex (MHC), leading to the priming and activation of naïve T cells, which traffic to and infiltrate the tumor. In the final step, activated cytotoxic CD8+ T cells and natural killer (NK) cells identify tumor cells and enact cytotoxic activity leading to cell death.

Negative regulators of T-cell activation exist as immune checkpoints, with programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen (CTLA-4), the most studied pathways. Tumor cells exploit such inhibitory pathways to evade host immune surveillance.^[@bibr9-1758835920937902]^ Interruption of these pathways with antibodies targeting PD-1/PD-L1 (pembrolizumab, nivolumab, atezolizumab, durvalumab), and CTLA-4 (ipilimumab, tremelimumab) work to facilitate host immune response against the tumor. The management of patients with advanced NSCLC with immune checkpoint blockade has been reviewed elsewhere.^[@bibr10-1758835920937902],[@bibr11-1758835920937902]^

Resistance to ICIs {#section3-1758835920937902}
==================

Resistance can be categorized as either primary (innate) or secondary (acquired) ([Figure 1](#fig1-1758835920937902){ref-type="fig"}).^[@bibr12-1758835920937902],[@bibr13-1758835920937902]^ However, defining such resistance has been challenging and no single accepted definition exists. Primary resistance has been defined as disease progression by RECIST criteria on first CT evaluation or death prior to first CT evaluation^[@bibr14-1758835920937902]^ whereas in another paper, it was defined as those that fail to ever respond.^[@bibr13-1758835920937902]^ It represents a major clinical problem in patients with advanced NSCLC with a frequency of 7--27% reported with first-line ICI with or without chemotherapy and 20--44% in the pre-treated setting with ICI monotherapy, assuming we take the definition for primary resistance as progressive disease (PD) as best response ([Table 1](#table1-1758835920937902){ref-type="table"}).

![A spider plot representing examples of resistance to immune checkpoint inhibition with (P) primary resistance, defined as best response being disease progression; (AR1) acquired resistance, defined as initial stable disease and subsequent disease progression; and (AR2) acquired resistance, defined as initial response and subsequent disease progression.](10.1177_1758835920937902-fig1){#fig1-1758835920937902}

###### 

Frequency of primary resistance (disease progression as best response) in selected studies of immune checkpoint inhibitors with or without chemotherapy.

![](10.1177_1758835920937902-table1)

                               *Study*                                  *Treatment*                                 *ORR (%)*   *PD as best response (%)*
  ---------------------------- ---------------------------------------- ------------------------------------------- ----------- ---------------------------
  **First line setting**                                                                                                        
  Monotherapy                  KN024^[@bibr15-1758835920937902]^        Pembrolizumab                               44.8        22
                               KN042^[@bibr16-1758835920937902]^        Pembrolizumab (TPS ⩾1%)                     27.3        21
                               CM026^[@bibr17-1758835920937902]^        Nivolumab                                   26          27
  Chemotherapy **+** **ICI**   KN189^[@bibr18-1758835920937902]^        Chemotherapy + Pembrolizumab                47.6        8.8
                               KN407^[@bibr19-1758835920937902]^        Chemotherapy + Pembrolizumab                58.4        6.9
                               IMpower130^[@bibr20-1758835920937902]^   Chemotherapy + Atezolizumab                 49.2        11
                               IMpower131^[@bibr21-1758835920937902]^   Chemotherapy + Atezolizumab                 49          Not reported
                               IMpower150^[@bibr22-1758835920937902]^   Chemotherapy + Bevacizumab + Atezolizumab   63.5        18
  ICI **+** ICI                CM227^[@bibr23-1758835920937902]^        Ipilimumab + Nivolumab (TMB high)           45.3        15.8
                               MYSTIC^[@bibr24-1758835920937902]^       Durvalumab + Tremelimumab                   34.4        Not reported
  **Pre-treated setting**                                                                                                       
  Monotherapy                  CM017^[@bibr25-1758835920937902]^        Nivolumab                                   20          41
                               CM057^[@bibr26-1758835920937902]^        Nivolumab                                   19          44
                               KN010^[@bibr27-1758835920937902]^        Pembrolizumab (TPS ⩾1%)                     18          20--25
                               OAK^[@bibr28-1758835920937902]^          Atezolizumab                                14          44

CM, CHECKMATE; ICI, immune checkpoint inhibitor; KN, KEYNOTE; ORR, overall response rate; PD, progressive disease; TPS, tumor proportion score.

Secondary resistance has been classified as disease progression after partial response (PR) or complete response (CR)^[@bibr13-1758835920937902],[@bibr29-1758835920937902]^ or initial clinical benefit followed by the development of resistance.^[@bibr14-1758835920937902]^

Defining resistance is complicated by the presence of atypical response patterns, such as pseudo-progression that has been reported with ICIs. Pseudo-progression has been defined as response to treatment after initial progression and was first observed in patients with melanoma treated with ipilimumab. The recognition of this uncommon entity, described in less than 10% of patients treated with ICIs, resulted in the development of the specific immune-related response criteria (irRC), as the original response evaluation criteria in solid tumors (RECIST) criteria was designed to assess response to conventional chemotherapy.^[@bibr30-1758835920937902][@bibr31-1758835920937902][@bibr32-1758835920937902]--[@bibr33-1758835920937902]^ These include immune-related RECIST (irRECIST) and, more recently, the consensus assessment guideline immunotherapy RECIST (iRECIST). Both share the need for confirmation of PD at least 4 weeks and up to 12 weeks (irRECIST) or 8 weeks (iRECIST) after an initial scan showing apparent progression. iRECIST describes initial progression as immune unconfirmed PD (iUPD), only becoming immune confirmed PD (iCPD) if there is further increase in target lesion measurement on follow up imaging studies.^[@bibr34-1758835920937902]^ Recognizing pseudo-progression is important for several reasons: first, to avoid premature cessation of potentially effective treatment; second, not to continue a costly, potentially toxic ineffective therapy; and, finally, not to delay administering a new line of therapy. One must remember that pseudo-progression is a rare event in NSCLC and true progression is the most likely occurrence in the event of new lesions or growth of existing target lesions. Therefore, we may suggest that for most patients classical RECIST is most relevant to assess the presence of PD and therefore resistance. In a subgroup of patients who have clinical improvement or stability with asymptomatic and relatively slow progression on initial imaging one can follow guidelines as per irRECIST/iRECIST and confirm findings with a follow-up scan at least 4 weeks later. Progression as best response would constitute primary resistance as opposed to PD on first CT assessment, thus allowing for repeat assessment in those patients with possible pseudo-progression. Secondary resistance, as suggested above should include those patients who progress after initial clinical benefit.

The importance of achieving treatment response to ICI was underlined in a recent pooled analysis of four studies of nivolumab in patients with pre-treated NSCLC where survival was influenced by treatment response category. The median survival in patients who had achieved a CR/PR, stable disease (SD), and progression of disease (PD) at 6 months was not reached, 15.5 months, and 7.3 months, respectively. Importantly, and not surprisingly, survival was worse in patients with primary resistance (progression as best response) compared with patients with secondary resistance (disease progression after SD, CR, or PR). The 3-year overall survival (OS) rate for patients who progressed after CR/PR, SD, and PD as best response was 29%, 12%, and 3%, respectively.^[@bibr35-1758835920937902]^ These results highlight the need to understand mechanisms of resistance and develop novel therapeutic approaches to overcome resistance.

Given the varying definitions of primary and secondary resistance, the frequencies of their occurrence and the differences in survival seen in patients displaying such resistance, efforts should be undertaken to standardize the definitions used in order to provide a consistent approach to the conduct, interpretation, and analysis of clinical studies. Analysis of trial datasets similar to Antonia *et al*.^[@bibr35-1758835920937902]^ on the association between response status and survival may aid in clarifying the definition of primary and secondary resistance. This process, as highlighted above, is however complicated by atypical response patterns seen with ICIs.

Clinical characteristics of resistance to ICIs {#section4-1758835920937902}
----------------------------------------------

Published reports on the clinical features of resistance to ICIs in advanced NSCLC have been sparse. In a study of patients (*n* = 93) with pre-treated advanced NSCLC who received ICI monotherapy, the authors defined primary resistance as disease progression on first radiologic evaluation or death prior to first CT evaluation, and reported it in 38.7% of patients.^[@bibr14-1758835920937902]^ The characteristics associated with such resistance included never smokers or those who smoked fewer pack years, more involved sites, more prior therapies, and a lower mean albumin level.^[@bibr14-1758835920937902]^ Factors associated with acquired resistance, defined as progression or death in patients after an initial clinical benefit were performance status and depth of response.^[@bibr14-1758835920937902]^ In another study (*n* = 26), the median time to acquired resistance was 313 days with a 2-year survival rate from acquired resistance of 70% and there was a reported tendency for progression at lymph nodes sites.^[@bibr29-1758835920937902]^

Biomarkers of resistance to ICI {#section5-1758835920937902}
===============================

Biomarkers for immune checkpoint inhibition that have been studied most are PD-L1 expression, tumor mutation burden (TMB) and T-cell infiltration.^[@bibr36-1758835920937902]^ Currently the only approved predictive biomarker for immune checkpoint blockade is PD-L1 expression using immunohistochemistry (IHC) with higher levels of expression associated with improved outcomes.^[@bibr11-1758835920937902]^ Conversely, a lower PD-L1 expression is associated with lower benefit,^[@bibr10-1758835920937902],[@bibr11-1758835920937902]^ but despite this, advanced NSCLC patients with negative PD-L1 expression can still obtain benefit from the addition of anti-PD1 therapy over standard therapy.^[@bibr18-1758835920937902],[@bibr19-1758835920937902],[@bibr37-1758835920937902]^ TMB, a potential predictive biomarker for ICI treatment, corresponds to somatic mutations detected by DNA sequencing. An increased number of nonsynonymous mutations results in higher neoantigen production and thus potentially increased immune recognition and response.^[@bibr38-1758835920937902]^ Studies have reported higher TMB is associated with improved outcomes.^[@bibr23-1758835920937902],[@bibr39-1758835920937902][@bibr40-1758835920937902][@bibr41-1758835920937902]--[@bibr42-1758835920937902]^ The intra-tumoral heterogeneity (ITH) can also affect immune response. Patients with high neoantigen burden and low ITH treated with immune checkpoint blockade had improved OS compared with those with a high ITH.^[@bibr43-1758835920937902]^ Decreased T-cell infiltration has been reported to be associated with a poorer prognosis^[@bibr44-1758835920937902],[@bibr45-1758835920937902]^ and to be predictive of a decreased response to immune checkpoint blockade.^[@bibr46-1758835920937902],[@bibr47-1758835920937902]^

Identifying biomarkers of ICI resistance is an emerging field and includes factors involving the tumor, the tumor microenvironment (TME), and the host ([Figure 2](#fig2-1758835920937902){ref-type="fig"}). Examples related to ICI resistance in NSCLC are highlighted where possible, but biomarkers in other solid tumors are also discussed where applicable.

![Biomarkers of primary and acquired resistance occurring in the (A) tumor microenvironment (TME), (B) in the tumor, and (C) host factors. Within the TME, factors involved in primary resistance (blue font) includes the presence of (a) immunosuppressive cells including cancer associated fibroblasts (CAFs), myeloid derived suppressor cells (MDSCs), regulatory T cells (T reg), M2 macrophages, and reduced tumor infiltrating lymphocytes (TILs), (b) immune-suppressive molecules such as indoleamine 2,3-dioxygenase (IDO), adenosine, vascular endothelial growth factor (VEGF), glucose, and (c) tumoral factors such as reduced PD-L1 expression, tumor mutation burden (TMB), intra-tumoral heterogeneity (ITH), genetic loss of HLA class I, dysregulated IFN/JAK pathway, aberrant oncologic signaling pathways (PTEN loss, mutations in WNT/b-catenin, LKB1, c-myc). Biomarkers associated with acquired resistance (red font) include (d) loss of B2m and MHC-I, neoantigen evolution with loss of neoepitopes; the IFN/JAK escape pathway with loss of function *JAK-1* and *JAK-2* mutations and (e) the upregulation of other immune checkpoints such as T-cell immunoglobulin, mucin domain-3 protein (TIM-3), lymphocyte-activation gene 3 (LAG-3), B and T lymphocyte attenuator (BTLA), T-cell immunoreceptor tyrosine-based inhibition motif domain (TIGIT), and V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA). Host factors affecting resistance includes (e) gut microbiome and antibiotic use.](10.1177_1758835920937902-fig2){#fig2-1758835920937902}

Tumor factors {#section6-1758835920937902}
-------------

Tumor biomarkers associated with resistance can be generally classified into the following: tumor antigen presentation, IFN/JAK escape pathway, aberrant oncologic signaling pathways, immunosuppressive immune cells/molecules, and other immune checkpoints ([Table 2](#table2-1758835920937902){ref-type="table"}).

###### 

Use of novel agents to overcome resistance.

![](10.1177_1758835920937902-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target                                     Examples                          Potential therapeutic approaches
  ------------------------------------------ --------------------------------- --------------------------------------------------------------------------------------
  Tumor antigen presentation                 B2m, HLA, neoantigen loss         Radiotherapy, chemotherapy, epigenetic therapies, cancer vaccines, oncolytic viruses

  IFN/JAK escape pathway                     JAK-1, JAK-2 mutations            STING agonists, bispecific T-cells

  Immunosuppressive immune cells/molecules   CAFs, MDSCs, Treg, macrophages\   Gemcitabine, entinostat, ATRA,\
                                             IDO, adenosine, VEGF, glucose     Targeting immuno-metabolism (glycolysis, adenosine, kynurenine pathways)\
                                                                               VEGF inhibitors

  Co-stimulatory signals                     OX-40, 41BB, CD40, GITR           Combination therapy targeting OX-40, 41BB, CD40, GITR

  Other immune checkpoint inhibitors         LAG-3, TIM-3, VISTA               Combination therapy targeting LAG-3, TIM-3
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATRA, all-trans retinoic acid; B2m, β2 microglobulin; CAF, cancer-associated fibroblast; GITR, glucocorticoid-induced tumor necrosis factor receptor-related protein; HLA, human leukocyte antigen; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFN, interferon; JAK, janus kinase; LAG3, lymphocyte-activation gene 3; MDSC, myeloid-derived suppressor cell; STING, stimulator of interferon genes; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; Treg, regulatory T cell; VEGF, vascular endothelial growth factor; VISTA, V-domain Ig suppressor of T-cell activation.

### Tumor antigen presentation {#section7-1758835920937902}

Disruptions in tumor antigen presentation such as alterations in antigen presentation pathways and neoantigen loss can contribute to both primary and acquired resistance.^[@bibr12-1758835920937902]^ Defects in antigen presentation pathways can be mediated through HLA I loss or β~2~-microglobulin (β~2~-m) function. The loss of HLA class I antigens is associated with reduced tumor infiltrating T-lymphocytes^[@bibr48-1758835920937902]^ and patients with a range of solid tumors and HLA I homozygosity treated with ICI had worse OS.^[@bibr49-1758835920937902]^ In contrast, there was no association between HLA class I genotype and outcomes in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors.^[@bibr50-1758835920937902]^ Further studies are required to elucidate the association between HLA I and outcomes with ICIs. Antigen presentation can be dysregulated in secondary resistance through HLA mutations or loss of heterozygosity.^[@bibr51-1758835920937902],[@bibr52-1758835920937902]^

Another mechanism of acquired resistance disrupting antigen presentation is the loss of functional β~2~-m^[@bibr53-1758835920937902]^ including a truncating mutation in β~2~-m.^[@bibr54-1758835920937902]^ Acquired resistance in NSCLC has also been associated with the elimination of mutation-associated neoantigens. The loss of neoantigens can occur *via* the elimination of tumor subclones or deletion of truncal chromosomal regions.^[@bibr55-1758835920937902]^

### IFN-γ/JAK-STAT escape pathway {#section8-1758835920937902}

IFN-γ induces anti-tumor immune response *via* the activation of Janus kinase 1 or 2 (JAK-1, JAK-2). In melanoma, *JAK1/2* loss of function mutations are associated with both primary and acquired resistance to ICI therapy due to an impaired response to IFN-γ stimulation.^[@bibr54-1758835920937902],[@bibr56-1758835920937902],[@bibr57-1758835920937902]^ A small number of samples in the NSCLC TCGA cohort showed inactivating mutations in *JAK2*^[@bibr58-1758835920937902]^ which was associated with significantly reduced PD-L1 expression although the correlation to ICI treatment response is yet to be elucidated in this setting.

### Aberrant oncologic signaling pathways {#section9-1758835920937902}

Dysregulation in oncologic signaling pathways can impair the immune response by altering the TME, resulting in resistance to ICI.^[@bibr59-1758835920937902]^

Upregulation of β-catenin signaling is associated with reduced T cell infiltration^[@bibr60-1758835920937902]^ and a "cold" non-inflamed tumor.^[@bibr61-1758835920937902]^ A gain of function alteration in *c-MYC* is associated with decreased T cell activation and infiltration.^[@bibr59-1758835920937902]^ Loss of phosphatase and tensin homolog (PTEN), a negative regulator or the PI3K/Akt/mTOR pathway, is linked to decreased tumor T cell infiltration and resistance to anti-PD1 therapy.^[@bibr62-1758835920937902][@bibr63-1758835920937902]--[@bibr64-1758835920937902]^ Mutations in the tumor suppressor *LKB1* with or without *KRAS* mutations are associated with an immunosuppressive TME and resistance to ICI.^[@bibr42-1758835920937902],[@bibr65-1758835920937902]^ Improved outcomes have been reported in patients in patients with NSCLC with *TP53* and or *KRAS* mutations treated with ICI.^[@bibr66-1758835920937902][@bibr67-1758835920937902]--[@bibr68-1758835920937902]^ In patients with NSCLC harboring *EGFR* mutations, treatment with pembrolizumab in the first-line setting was ineffective.^[@bibr69-1758835920937902]^ In addition, in the pre-treated setting, the effect of ICI monotherapy appears blunted in *EGFR* mutated NSCLC^[@bibr70-1758835920937902]^ with a similar OS to docetaxel, whereas PD-1/PD-L1 inhibition was superior to docetaxel in wild-type *EGFR* NSCLC.^[@bibr71-1758835920937902]^ These observations are explained in part by the fact constitutive EGFR activation leads to IFN-γ independent PD-L1 expression and increased levels of immunosuppressive cytokines.^[@bibr72-1758835920937902]^

### Hypoxic TME {#section10-1758835920937902}

Hypoxia and acidosis from tumor glycolytic metabolism have immunosuppressive effects on the TME,^[@bibr73-1758835920937902]^ resulting in reduced CD8+ T-cell activity, upregulation of Treg, and macrophage switch from an inflammatory M1 phenotype to immunosuppressive M2.^[@bibr74-1758835920937902][@bibr75-1758835920937902]--[@bibr76-1758835920937902]^ Studies of lung cancer cell lines have reported hypoxia-induced resistance to cytotoxic T lymphocyte mediated lysis^[@bibr77-1758835920937902]^ and, more recently, tumor-associated macrophages (TAMs) were reported to enhance tumor hypoxia in NSCLC and modulate the activity of immune checkpoint inhibition.^[@bibr78-1758835920937902]^

### Immunosuppressive immune cells/molecules {#section11-1758835920937902}

Vascular endothelial growth factor (VEGF) is associated with an immunosuppressive TME and resistance to immunotherapy^[@bibr79-1758835920937902][@bibr80-1758835920937902]--[@bibr81-1758835920937902]^ by inhibiting DC maturation, decreasing T-cell tumor infiltration, and increasing MDSCs and Treg.^[@bibr82-1758835920937902][@bibr83-1758835920937902]--[@bibr84-1758835920937902]^ Retrospective analysis shows a high ORR achieved with the combination of docetaxel and the VEGF receptor 2 inhibitor, ramucirumab, in patients with prior exposure to nivolumab.^[@bibr85-1758835920937902]^ Indoleamine 2,3-dioxygenase 1 (IDO1) catabolizes tryptophan to kynurenine and has been associated with suppression of T effector cell function and induction of Treg activation and antigen-specific immune tolerance, leading to ICI resistance.^[@bibr86-1758835920937902]^ Increased ratio of kynurenine: tryptophan is associated with shorter survival in NSCLC and early progression on anti-PD1 therapy.^[@bibr86-1758835920937902],[@bibr87-1758835920937902]^

### Immune checkpoints {#section12-1758835920937902}

Upregulation of other immune checkpoints such as T-cell immunoglobulin and mucin domain-3 protein (TIM-3), lymphocyte-activation gene 3 (LAG-3), B and T lymphocyte attenuator (BTLA), T-cell immunoreceptor tyrosine-based inhibition motif domain (TIGIT), and/or V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) has been seen in several solid-organ malignancies. In NSCLC TIM-3 upregulation was seen in patients exhibiting secondary resistance to ICI.^[@bibr88-1758835920937902][@bibr89-1758835920937902][@bibr90-1758835920937902][@bibr91-1758835920937902]--[@bibr92-1758835920937902]^

Host factors {#section13-1758835920937902}
------------

A link between the gut microbiome and response to immunotherapy has been reported. Sarcomas (MCA205) in mice fed a germ-free diet failed to respond to CTLA-4 blockade and upon administration of *Bacteroides fragilis*, anti-tumor response was restored.^[@bibr93-1758835920937902]^ Gut microbiome diversity and enrichment of certain bacterial species such *Bifidobacterium, Akkermansia*, and *Faecalibacterium* has been associated with sensitivity to immune checkpoint blockade in patients with NSCLC, urothelial cancer, renal cell carcinoma (RCC) and melanoma whereas *Bacteroidales* species has been associated with decreased response.^[@bibr94-1758835920937902][@bibr95-1758835920937902]--[@bibr96-1758835920937902]^

The importance of such diversity may explain the negative effects of antibiotics on ICI treatment response seen in patients with melanoma, RCC, and NSCLC.^[@bibr97-1758835920937902][@bibr98-1758835920937902]--[@bibr99-1758835920937902]^ The mechanism by which the microbiome influences response to ICI is yet to be fully elucidated but it is possible the microbiota influences anti-tumor immunity through gut metabolites facilitating T helper response and maturation of DCs.^[@bibr93-1758835920937902],[@bibr96-1758835920937902],[@bibr100-1758835920937902]^

Treatment approaches to overcome resistance {#section14-1758835920937902}
===========================================

To reduce the rate of primary resistance, therapeutic strategies include combining ICI with chemotherapy and/or novel agents. In patients with progression after exposure to ICI, approaches include cessation of ICI and switching to chemotherapy, addition of chemotherapy to ICI, or the addition of a novel agent to ICI. Selected ongoing trials of combination treatment in patients who are immunotherapy naïve and with prior immunotherapy exposure are summarized in [Table 3](#table3-1758835920937902){ref-type="table"}.

###### 

Selected studies of ICIs combined with novel agents to overcome resistance.

![](10.1177_1758835920937902-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Potential treatment approaches                  Study phase   ICI therapy status (naïve or prior)   Treatment                                                                                               Cancer type                                     [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier
  ----------------------------------------------- ------------- ------------------------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------
  **Tumor antigen presentation**                                                                                                                                                                                                                              

  **ICI + Oncolytic viruses**                     I/II          Naïve/prior                           Durvalumab + Pexa-Vec *versus*\                                                                         Colorectal                                      NCT03206073
                                                                                                      Durvalumab + Tremelimumab + Pexa-Vec                                                                                                                    

                                                  II            Naïve                                 Pembrolizumab + Pelareorep                                                                              Pancreatic                                      NCT03723915

                                                  I/II          Naïve/prior                           Pembrolizumab + CVA21                                                                                   NSCLC                                           NCT02824965

                                                  I             Naïve/prior                           Pembrolizumab + CVA21                                                                                   NSCLC, bladder, prostate, melanoma              NCT02043665

                                                  II            Naïve                                 Pembrolizumab + DNX-2401                                                                                Glioblastoma, gliosarcoma                       NCT02798406

                                                  I/II          Naïve                                 Nivolumab + Intra-pleural Talimogene Laherparepvec                                                      Advanced solid tumors with malignant effusion   NCT03597009

                                                  II            Prior                                 Pembrolizumab + Talimogene Laherparepvec                                                                Melanoma                                        NCT02965716

                                                  Ib            Naïve/prior                           Atezolizumab + Talimogene Laherparepvec                                                                 TNBC, colorectal                                NCT03256344

                                                  II            Naïve                                 Pembrolizumab + ADV/HSV-tk + SBRT                                                                       TNBC, NSCLC                                     NCT03004183

  **ICI + Targeted therapy**                      I             Naïve                                 Pembrolizumab + Afatinib                                                                                NSCLC                                           NCT02364609

                                                  II            Naïve                                 Pembrolizumab + Afatinib                                                                                Lung (SCC)                                      NCT03157089

                                                  I             Naïve/prior                           Ipilimumab or Nivolumab + Erlotinib or Crizotinib                                                       NSCLC                                           NCT01998126

                                                  I/II          Naïve/prior                           Nivolumab + Nimotuzumab                                                                                 NSCLC                                           NCT02947386

                                                  II            Naïve                                 Nivolumab + EGF816 or INC280                                                                            NSCLC                                           NCT02323126

                                                  I             Naïve                                 Pembrolizumab + Binimetinib                                                                             NSCLC                                           NCT03991819

                                                  II            Prior                                 Atezolizumab + Cobimetinib                                                                              NSCLC                                           NCT03600701

                                                  I/II          Naïve/prior                           Durvalumab + Tremelimumab, +Selumetinib                                                                 NSCLC                                           NCT03581487

                                                  I             Naïve/prior                           Pembrolizumab + Trametinib                                                                              NSCLC                                           NCT03299088

                                                  I/II          Naïve/prior                           Pembrolizumab + Trametinib                                                                              NSCLC                                           NCT03225664

                                                  III           Naïve                                 Maintenance Pembrolizumab + Olaparib or pemetrexed (after induction Pembrolizumab/Platinum/Pemetrexed   NSCLC                                           NCT03976323

                                                  I             Naïve/prior                           Durvalumab + AZD5363 + Olaparib                                                                         Solid tumors                                    NCT03772561

  **ICI + Cancer vaccines**                       I/II          Naïve/prior                           Nivolumab or Pembrolizumab + CIMAvax                                                                    NSCLC, HNSCC                                    NCT02955290

                                                  I             Naïve                                 Pembrolizumab + NEO-PV-01                                                                               NSCLC (non-squamous)                            NCT03380871

                                                  I/II          Naïve/prior                           Pembrolizumab + Galinpepimut-S                                                                          Solid tumors                                    NCT03761914

                                                  Ib            Naïve                                 Pembrolizumab + PVX-410                                                                                 TNBC (HLA-A2+)                                  NCT03362060

  **ICI + Chemotherapy**                          Ib            Naïve                                 Pembrolizumab + Liposomal Doxorubicin                                                                   Breast (endocrine resistant)                    NCT03591276

                                                  II            Naïve/prior                           Atezolizumab + Vinorelbine                                                                              NSCLC                                           NCT03801304

  **ICI + Radiotherapy**                          I             Naïve                                 Ipilimumab + Nivolumab + RT                                                                             NSCLC                                           NCT04013542

                                                  II            Naïve                                 Anti-PD1 + Radiotherapy                                                                                 Melanoma                                        NCT04017897

  **ICI + ACT**                                   I             Prior                                 FT500 *versus*\                                                                                         Advanced solid tumors, lymphoma                 NCT03841110
                                                                                                      FT500 + ICI (nivolumab, pembrolizumab, atezolizumab)                                                                                                    

                                                  I             Naïve                                 Nivolumab + Cyclophosphamide + Fludarabine + TIL + IL-2                                                 NSCLC                                           NCT03215810

                                                  II            Naïve/prior                           GSK3377794 *versus*\                                                                                    NSCLC                                           NCT03709706
                                                                                                      Pembrolizumab + GSK3377794                                                                                                                              

                                                  II            Naïve                                 Anti-PD-1 + D-CIK                                                                                       Advanced solid tumors                           NCT02886897

  **ICI + HDAC inhibitors**                       I/II          Naïve/prior                           Pembrolizumab + Entinostat                                                                              NSCLC, melanoma, colorectal (MSS)               NCT02437136

                                                  I/II          Naïve/prior                           Pembrolizumab + Vorinostat                                                                              NSCLC                                           NCT02638090

  **IFN/JAK escape pathway**                                                                                                                                                                                                                                  

  **ICI + Sting agonists**                        I             Naïve/prior                           GSK3745417 *versus*\                                                                                    Advanced solid tumors                           NCT03843359
                                                                                                      Pembrolizumab + GSK3745417                                                                                                                              

                                                  I             Naïve/prior                           PDR001 + MIW815                                                                                         Advanced solid tumors, lymphomas                NCT03172936

                                                  I             Naïve/prior                           MIW815 ± Ipilimumab                                                                                     Advanced solid tumors, lymphomas                NCT02675439

  **ICI + JAK inhibitor**                         II            Naïve                                 Pembrolizumab + Itacitinib                                                                              NSCLC                                           NCT03425006

  **ICI + PI3Ki**                                 Ib/II         Prior                                 Pembrolizumab + idelalisib                                                                              NSCLC                                           NCT03257722

  **Immunosuppressive immune cells/molecules**                                                                                                                                                                                                                

  **ICI + VEGF inhibitor**                        I/II          Naïve/prior                           Nivolumab + Ipilimumab + Nintedanib                                                                     NSCLC                                           NCT03377023

                                                  II            Naïve/prior                           Nivolumab + Ramucirumab                                                                                 NSCLC                                           NCT03527108

                                                  I/II          Naïve                                 Pembrolizumab + Lenvatinib                                                                              NSCLC, RCC, endometrial, urothelial, HNSCC      NCT02501096

                                                  III           Naïve                                 Pembrolizumab+ Platinum chemotherapy + Pemetrexed ± Lenvatinib                                          NSCLC (non-squamous)                            NCT03829319

                                                  II            Naïve                                 Atezolizumab + Bevacizumab                                                                              NSCLC                                           NCT04099836

                                                  I             Naïve                                 Nivolumab or Pembrolizumab + Vorolanib                                                                  HCC, gastric, GEJ                               NCT03511222

  **ICI + IDO inhibitor**                         II            Naïve                                 Pembrolizumab ± Epacadostat                                                                             NSCLC                                           NCT03322540

                                                  II            Naïve                                 Pembrolizumab + Platinum doublet + Epacadostat                                                          NSCLC                                           NCT03322566

                                                  I/II          Naïve                                 Pembrolizumab + IO102 ± Platinum doublet                                                                NSCLC                                           NCT03562871

                                                  II            Naïve                                 Nivolumab ± BMS986205                                                                                   HNSCC                                           NCT03854032

                                                  I/II          Naïve                                 Pembrolizumab, Nivolumab or Ipilimumab + Indoximod                                                      Melanoma                                        NCT02073123

  **ICI + Adenosine receptor antagonist**         I/Ib          Naïve/prior                           PBF509 *versus*\                                                                                        NSCLC                                           NCT02403193
                                                                                                      PBF509+PDR001                                                                                                                                           

                                                  I             Naïve/prior                           AB928 + chemotherapy *versus*\                                                                          NSCLC                                           NCT03846310
                                                                                                      AB928 + Pembrolizumab + chemotherapy *versus*\                                                                                                          
                                                                                                      AB122                                                                                                                                                   

                                                  I/Ib          Naïve/prior                           CPI-444\                                                                                                Advanced solid tumors                           NCT02655822
                                                                                                      Atezolizumab + CPI-444                                                                                                                                  

                                                  I             Naïve/prior                           MK-3814\                                                                                                Advanced solid tumors                           NCT03099161
                                                                                                      Pembrolizumab + MK-3814                                                                                                                                 

  **ICI + CD73 inhibitor**                        I             Naïve/prior                           NZV930 *versus*\                                                                                        Advanced solid tumors                           NCT035490002
                                                                                                      PDR001 + NZV930                                                                                                                                         

                                                  I/II          Naïve/prior                           BMS-986179\                                                                                             Advanced solid tumors                           NCT02754141
                                                                                                      Nivolumab + BMS-986179\                                                                                                                                 
                                                                                                      Nivolumab + BMS-986179 + rHuPH20                                                                                                                        

                                                  I             Naïve/prior                           Oleclumab *versus*\                                                                                     Solid tumors                                    NCT02503774
                                                                                                      Durvalumab + Oleclumab                                                                                                                                  

                                                  I             Naïve                                 Durvalumab + Oleclumab\                                                                                 NSCLC                                           NCT03819465
                                                                                                      Durvalumab + Oleclumab + Chemotherapy                                                                                                                   

  **ICI + RANKL inhibitor**                       II            Naïve                                 Nivolumab + Denosumab                                                                                   NSCLC                                           NCT03669523

  **ICI + CD39 inhibitor**                        I             Naïve/prior                           TTX030 *versus*\                                                                                        Advanced solid tumors, lymphoma                 NCT03884556
                                                                                                      Pembrolizumab + TTX030 *versus*\                                                                                                                        
                                                                                                      Chemotherapy + TTX030                                                                                                                                   

  **ICI + anti-IL-1β**                            III           Naïve                                 Platinum doublet + Pembrolizumab ± Canakinumab                                                          NSCLC                                           NCT03631199

  **Co-stimulatory signals**                                                                                                                                                                                                                                  

  **ICI + r-interleukin**                         I             Naïve/prior                           rIL-15 + Nivolumab *versus*\                                                                            Advanced solid tumors                           NCT03388632
                                                                                                      rIL-15 + Ipilimumab *versus*\                                                                                                                           
                                                                                                      rIL-15 + Nivolumab + Ipilimumab                                                                                                                         

                                                  I             Naïve                                 Pembrolizumab + rIL-12                                                                                  Advanced solid tumors                           NCT03030378

  **PD-L1x4-1BB bispecific antibody**             I             Naïve/prior                           INBRX-105                                                                                               Solid tumors, lymphoma                          NCT03809624

                                                  I             Naïve/prior                           ES101                                                                                                   Solid tumors                                    NCT04009460

  **ICI + Anti-ICOS**                             I/II          Naïve/prior                           KY1044 *versus*,\                                                                                       Advanced solid tumors                           NCT03829501
                                                                                                      Atezolizumab + KY1044                                                                                                                                   

                                                  II            Naïve/prior                           Tremelimumab + GSK3359609                                                                               Advanced solid tumors                           NCT03693612

  **ICI + Anti-GITR**                             I/II          Naïve/prior                           Ipilimumab + Nivolumab + BMS-986156 ± SBRT                                                              Advanced solid tumors                           NCT04021043

                                                  I/Ib          Naïve/prior                           GWN323 *versus*\                                                                                        Advanced solid tumors, lymphoma                 NCT02740270
                                                                                                      PDR001 + GWN323                                                                                                                                         

  **ICI + Microbiota**                            I             Naïve/prior                           Anti-PD-1/PD-L1 + MET4                                                                                  Advanced solid tumors                           NCT03686202

                                                  I             --                                    Anti-PD1/PDL1 + Fecal microbial transplantation                                                         Melanoma                                        NCT03772899

                                                  I             Naïve                                 Nivolumab + Ipilimumab ± CBM588                                                                         RCC                                             NCT03829111

                                                  II            Naïve                                 Pembrolizumab + Fecal transplant                                                                        Prostate                                        NCT04116775

  **ICI + TLR9 agonist**                          I             Naïve/prior                           Nivolumab + DV281                                                                                       NSCLC                                           NCT03326752

                                                  I/II          Naïve/prior                           Pembrolizumab + intra-tumoral AST-008                                                                   Advanced solid tumors                           NCT03684785

  **Co-inhibitory or other immune checkpoints**                                                                                                                                                                                                               

  **Anti-PD(L)1 + Anti-CTLA4**                    III           Naïve                                 Nivolumab *versus*\                                                                                     NSCLC                                           NCT02477826
                                                                                                      Nivolumab + Ipilimumab *versus*\                                                                                                                        
                                                                                                      Nivolumab + Platinum doublet *versus*\                                                                                                                  
                                                                                                      Platinum doublet                                                                                                                                        

                                                  III           Naïve                                 Nivolumab + Ipilimumab\                                                                                 NSCLC                                           NCT03351361
                                                                                                      Carboplatin doublet                                                                                                                                     

                                                  III           Naïve                                 REGN2810 + ipilimumab *versus*\                                                                         NSCLC                                           NCT03515629
                                                                                                      REGN2810 + platinum doublet + Ipilimumab *versus*\                                                                                                      
                                                                                                      Pembrolizumab                                                                                                                                           

                                                  III           Naïve                                 Durvalumab + Tremelimumab *versus*\                                                                     NSCLC                                           NCT02542293
                                                                                                      Chemotherapy                                                                                                                                            

                                                  III           Naïve                                 Pembrolizumab ± Ipilimumab                                                                              NSCLC                                           NCT03302234

                                                  III           Naïve                                 Nivolumab + chemotherapy *versus*\                                                                      NSCLC                                           NCT02864251
                                                                                                      Nivolumab + Ipilimumab *versus*\                                                                                                                        
                                                                                                      Chemotherapy                                                                                                                                            

                                                  II            Naïve                                 Nivolumab + Ipilimumab + Temozolomide                                                                   Colorectal (MSS, MGMT promoter methylated)      NCT03832621

  **ICI + LAG-3 inhibitor**                       II            Naïve/prior                           Pembrolizumab + Eftilagimod Alpha                                                                       NSCLC\                                          NCT03625323
                                                                                                                                                                                                              HNSCC                                           

                                                  I/II          Naïve/prior                           LAG525 ± PDR001                                                                                         Advanced solid tumors                           NCT02460224

                                                  I             Naïve/prior                           BI 754111 + BI 754091                                                                                   Advanced solid tumors                           NCT03156114

                                                  II            Prior                                 Nivolumab + Relatlimab                                                                                  Colorectal (MSI-H)                              NCT03607890

                                                  II            Naïve                                 Nivolumab + Relatlimab                                                                                  Colorectal (MSS)                                NCT03642067

                                                  II            Naïve                                 Nivolumab + Relatlimab                                                                                  Melanoma                                        NCT03743766

  **ICI + TIM-3 inhibitor**                       II            Naïve                                 TSR-042 + TSR-022                                                                                       HCC                                             NCT03680508

                                                  I             Naïve/prior                           TSR-022\                                                                                                Advanced solid tumors                           NCT02817633
                                                                                                      TSR-022 + nivolumab\                                                                                                                                    
                                                                                                      TSR-022 + TSR-042\                                                                                                                                      
                                                                                                      TSR-022 + TSR-042 + TSR-033                                                                                                                             

                                                  I/II          Naïve/prior                           Tislelizumab + BGB-A425                                                                                 Advanced solid tumors                           NCT03744468

                                                  I             Naïve/prior                           RO7121661 (bispecific antibody)                                                                         Advanced solid tumors                           NCT03708328

  **ICI + anti-TGIT**                             I             Naïve/prior                           AB122\                                                                                                  Advanced solid tumors                           NCT03628677
                                                                                                      AB122 + AB154                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACT, adoptive cell therapy; AML, acute myelogenous leukemia; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CVA21, coxsackie virus 21; GEJ, gastro-esophageal junction; GITR, glucocorticoid-induced tumor necrosis factor receptor-related protein; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; ICOS, inducible co-stimulator; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFN, interferon; JAK, janus kinase; LAG3, lymphocyte-activation gene 3; MET-4, microbial ecosystem therapeutics; MGMT, methylguanine-DNA methyltransferase; MSI-H, microsatellite instability high; MSS, microsatellite stable; NSCLC, non-small cell lung carcinoma; PI3Ki, phosphatidylinositol-3-kinase inhibitor; RCC, renal cell carcinoma; rIL-12, recombinant interleukin-12; rIL-15, recombinant interleukin 15; STING, stimulator of interferon genes; TGIT, T-cell immunoreceptor with Ig and ITIM domains; TIL, tumor-infiltrating lymphocyte; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; TLR, Toll-like receptor; TNBC, triple negative breast cancer; VEGF, vascular endothelial growth factor.

Addition of chemotherapy to ICI {#section15-1758835920937902}
-------------------------------

In the first-line setting, pembrolizumab monotherapy is superior to chemotherapy in NSCLC with a PD-L1 expression of ⩾1%, but progression as best response is seen in about 21--22% of patients ([Table 1](#table1-1758835920937902){ref-type="table"}).^[@bibr15-1758835920937902],[@bibr16-1758835920937902]^ Addition of doublet chemotherapy to pembrolizumab in this setting reduces the rate of such primary resistance to 6.9--8.8%, as reported in KEYNOTE 189 and 407.^[@bibr18-1758835920937902],[@bibr19-1758835920937902]^ The benefit of chemotherapy in such a combination is due to induction of immunogenic cell death and modulation of immune response^[@bibr8-1758835920937902]^ and in the first-line advanced setting is associated with improved outcomes compared with chemotherapy alone.^[@bibr18-1758835920937902],[@bibr19-1758835920937902],[@bibr22-1758835920937902]^

The benefit of adding chemotherapy to patients progressing on an ICI is being examined. For example, a phase II study \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03083808\] is enrolling patients with prior platinum-based chemotherapy and prior PD-1 or PD-L1 inhibitor as their most recent treatment who have had at least a 3-month PFS on this therapy. Patients will be treated with pembrolizumab combined with either gemcitabine, docetaxel, or pemetrexed.

An ECOG-ACRIN phase III study will also examine the effect of adding chemotherapy following pembrolizumab failure. Patients with advanced non-squamous NSCLC with PD-L1 expression of at least 1% will be treated with pembrolizumab and, upon progression, will switch to chemotherapy. In the second arm, patients will be treated with first-line pembrolizumab and at the time of disease progression, chemotherapy will be added to pembrolizumab, and in the third arm, acting as control, patients will receive chemotherapy and pembrolizumab \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT03793179\].

Switching to chemotherapy with or without an anti-angiogenic agent {#section16-1758835920937902}
------------------------------------------------------------------

In the setting where patients have progressed on an ICI, cessation of therapy and switching to chemotherapy, either to a platinum doublet if ICI monotherapy was given in the first-line setting, or docetaxel with or without an anti-angiogenic agent if an ICI and a platinum doublet was administered previously. Retrospective studies have suggested improved response rates with cytotoxic chemotherapy in patients following progression after ICI treatment ([Table 4](#table4-1758835920937902){ref-type="table"}). Schvartsman *et al*. reported an overall response rate (ORR) of 39% with single-agent chemotherapy in patients who have received prior platinum chemotherapy and PD-1/PD-L1 inhibitor.^[@bibr101-1758835920937902]^ In a Korean study, patients progressing on first-line PD-1/PD-L1 inhibitor were treated with a platinum doublet or single-agent chemotherapy, with a reported ORR of 66.7% and 46.9%, respectively.^[@bibr102-1758835920937902]^ Responses seen with first-line platinum doublet are typically 27--32% as reported in the control arms of KEYNOTE 024 and KEYNOTE 042.^[@bibr15-1758835920937902],[@bibr16-1758835920937902]^

###### 

Studies of subsequent chemotherapy with or without anti-angiogenic agent in patients with prior immune checkpoint inhibitor therapy.

![](10.1177_1758835920937902-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                               *N*   Prior treatment                               Treatment                          ORR      Survival
  --------------------------------------------------- ----- --------------------------------------------- ---------------------------------- -------- --------------
  Schvartsman *et al*.^[@bibr101-1758835920937902]^   28    Platinum chemotherapy, PD-1/PD-L1 inhibitor   Single-agent chemotherapy          39%      4.7 m (PFS)

  Grigg *et al*.^[@bibr103-1758835920937902]^         38    PD-1/PD-L1 inhibitor                          Platinum doublet ±  bevacizumab\   25%      3.8 m (TTP)
                                                                                                          Ramucirumab  +  docetaxel\                  
                                                                                                          Single-agent chemotherapy                   

  Leger *et al*.^[@bibr104-1758835920937902]^         67    PD-1/PD-L1 inhibitor                          Single-agent chemotherapy          27%      NR

  Park *et al*.^[@bibr102-1758835920937902]^          24\   PD-1/PD-L1 inhibitor                          Platinum doublet\                  66.7%\   4.5 m (PFS)\
                                                      49                                                  monotherapy                        46.9%    3.8 m (PFS)

  Grohe *et al*. ^[@bibr105-1758835920937902]^        22    Platinum chemo, pembrolizumab/ nivolumab      Nintedanib  +  docetaxel           58%      5.5 m (PFS)

  Corral *et al*.^[@bibr106-1758835920937902]^        11    Platinum chemotherapy, PD-1/PD-L1 inhibitor   Nintedanib  +  docetaxel           36.5%    NR

  Capelletto *et al*.^[@bibr107-1758835920937902]^    16    Chemotherapy, PD-1/PD-L1 inhibitor            Nintedanib  +  docetaxel           NR       5.84 m (PFS)

  Molife *et al*.^[@bibr108-1758835920937902]^        265   Chemotherapy, PD-1/PD-L1 inhibitor            Ramucirumab  +  chemotherapy       NR       26.5 m (OS)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

m, months; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTP, time to progression.

In patients who have received a prior platinum doublet and an ICI, the ORR with docetaxel combined with nintedanib was reported to be 36.5%^[@bibr106-1758835920937902]^ and 58%^[@bibr105-1758835920937902]^ ([Table 4](#table4-1758835920937902){ref-type="table"}). These results compare favorably with the docetaxel arm in CHECKMATE 057, CHECKMATE 017, and KEYNOTE 010, with an ORR of 9--12% and in studies of docetaxel combined with nintedanib (LUME-Lung 1), or ramucirumab (REVEL) with ORR of 4.4% and 23%, respectively.^[@bibr109-1758835920937902],[@bibr110-1758835920937902]^ The biological basis to explain the efficacy of combination docetaxel with an anti-angiogenic agent is unknown but possible explanations include the inhibition of the immunosuppressive VEGF pathway which may alter the TME to an immune-permissive state, leading to leading to anti-tumor immunity.^[@bibr83-1758835920937902]^ However, given the retrospective nature and small sample size in the majority of these studies, prospective studies on the role of combining chemotherapy with an anti-angiogenic agent should be performed.

Addition of a novel agent to an ICI {#section17-1758835920937902}
-----------------------------------

Combining an ICI with a novel agent in the first-line or subsequent therapy setting is an area of intense research interest. Potential therapeutic strategies to overcome resistance and increase sensitivity to immunotherapy include targeting the tumor antigen presentation pathway, the IFN/JAK escape pathway, immunosuppressive immune cells/molecules, co-inhibitory or other immune checkpoints and co-stimulatory signals ([Table 2](#table2-1758835920937902){ref-type="table"}). Examples for each approach will be discussed and selected ongoing studies are summarized in [Table 3](#table3-1758835920937902){ref-type="table"}.

### Targeting tumor antigen presentation pathway {#section18-1758835920937902}

Approaches to improve tumor antigenicity include combining an ICI with modalities such as chemotherapy, epigenetic therapies, radiotherapy (RT), cancer vaccines, or oncolytic viruses.

Cytotoxic chemotherapy increases the efficacy of ICI by inducing immunogenic cell death and modulating immune response^[@bibr8-1758835920937902]^ as mentioned previously. Epigenetic mechanisms play a role in immunosuppression^[@bibr111-1758835920937902]^ and DNA methyltransferase and histone deacetylase (HDAC) inhibitors can induce an immunostimulatory response by inhibiting Treg, MDSCs, and upregulating antigen presentation and cytokine production.^[@bibr112-1758835920937902]^ A phase II study of pembrolizumab plus the HDAC inhibitor entinostat, in patients with advanced NSCLC with prior progression on PD-1/PD-L1 inhibitor (ENCORE-601), reported a response rate of only 11%.^[@bibr113-1758835920937902]^ Although the prespecified ORR target was not reached, insight gained through biomarker studies may aid in patient selection for future studies.^[@bibr113-1758835920937902],[@bibr114-1758835920937902]^

An alternative strategy is to combine RT with an ICI. RT induces immunogenic cell death and increases tumor antigen presentation. A phase II study (PEMBRO-RT) compared pembrolizumab with or without single-site-directed RT.^[@bibr115-1758835920937902]^ A non-significant improvement in outcomes was seen and further studies are required to evaluate its potential benefit. Cancer vaccines such as DC vaccines, peptide vaccines, and neoantigen vaccines, can improve antigen presentation and recognition, increase tumor antigen-specific CTLs and enhance tumor T-cell infiltration, respectively, thus restoring anti-tumor immunity.^[@bibr116-1758835920937902]^ A phase I study of a personalized neoantigen vaccine (NEO-PV-01) plus nivolumab in PD-1/PD-L1 naïve NSCLC reported a response rate of 25%.^[@bibr117-1758835920937902]^ Oncolytic viruses can selectively infect tumor cells, induce tumor cell lysis, leading to systemic anti-tumor immunity.^[@bibr118-1758835920937902]^ In fact, Talimogene laherparepvec (T-VEC) is the first FDA-approved virotherapeutic approach in the treatment of patients with unresectable melanoma.^[@bibr119-1758835920937902]^ In a phase I study (KEYNOTE-200), patients with advanced NSCLC were treated with coxsackievirus 21, an oncolytic virus, plus pembrolizumab. The overall response was 23% in ICI naïve patients.^[@bibr120-1758835920937902]^

### Targeting the IFN/JAK escape pathway {#section19-1758835920937902}

The stimulator of interferon genes (STING) pathway plays an important role in adaptive anti-tumor response and represents an attractive immuno-therapeutic target. Pre-clinical models resistant to ICI were re-sensitized when combined with STING agonists.^[@bibr121-1758835920937902]^ In a phase I study where patients were treated with intra-tumoral MK-1454, a STING agonist, as monotherapy or in combination with pembrolizumab, the ORR was 0% and 25%, respectively,^[@bibr122-1758835920937902]^ suggesting combination therapy may be the optimal approach.

### Oncologic signaling pathways {#section20-1758835920937902}

Combining a PD-1/PD-L1 inhibitor with molecular targeted agents improves anti-tumor activity in *BRAF* mutant melanoma^[@bibr123-1758835920937902][@bibr124-1758835920937902]--[@bibr125-1758835920937902]^ and has been shown to be a successful treatment approach in patients with advanced RCC.^[@bibr126-1758835920937902],[@bibr127-1758835920937902]^ However, early phase studies in oncogene-driven NSCLC treated with ICI and an EGFR or ALK TKI, highlighted increased and unexpected toxicities, and reported response rates were lower than observed with single-agent targeted therapy.^[@bibr128-1758835920937902],[@bibr129-1758835920937902]^ Further evaluation of the optimal sequence, schedule, and dosing of such combinations will be required.^[@bibr59-1758835920937902],[@bibr72-1758835920937902]^.

### Immunosuppressive immune cells/molecules {#section21-1758835920937902}

The combination of VEGF inhibitors and ICI can negate an immune-suppressive TME and reverse resistance to immunotherapy.^[@bibr82-1758835920937902],[@bibr83-1758835920937902],[@bibr130-1758835920937902]^ For example, bevacizumab plus atezolizumab and chemotherapy is associated with an improvement in PFS and OS in patients with advanced NSCLC.^[@bibr22-1758835920937902]^ In the pre-treated setting sitravatinib (MGCD516), a tyrosine kinase inhibitor targeting VEGFR2, PDGFRA, KIT, Tyro, AXL, and MER may restore or enhance the activity of immune checkpoint blockade in NSCLC patients with immunotherapy resistance.^[@bibr131-1758835920937902]^ A phase II study of sitravatinib plus nivolumab in NSCLC was reported to show a response rate of 16% in patients who have progressed following prior ICI.^[@bibr132-1758835920937902]^ In a phase II study of patients with prior anti-PD-1/PDL1 therapy, the combination of pembrolizumab and lenvatinib, a VEGFR/FGFR/PDGFRα, RET, and KIT inhibitor, reported an ORR of 33.3%.^[@bibr133-1758835920937902]^ Another approach to overcome resistance is by targeting macrophages. The CD47-SIRPα axis signals the macrophage to ignore cells in which CD47 is expressed and tumors upregulate CD47 to evade immune response.^[@bibr134-1758835920937902]^ ALX148 is an antibody that binds and blocks CD47, resulting in enhanced macrophage phagocytosis and an increased ratio of inflammatory M1 TAMs to immunosuppressive M2 TAMs.^[@bibr135-1758835920937902]^ In a phase I study of patients with advanced solid tumors treated with ALX148 and pembrolizumab, the disease control rate (DCR) in NSCLC patients with or without prior ICI was 17%.^[@bibr136-1758835920937902]^

### Increasing co-stimulatory signals {#section22-1758835920937902}

T-cell activation can be augmented by agonists stimulating targets such as OX40, 4-1BB, glucocorticoid-induced TNFR-related protein (GITR), and inducible T-cell co-stimulator (ICOS). Co-stimulation induces cytotoxic T-cell proliferation, increased survival and effector function.^[@bibr137-1758835920937902]^ In a phase I study of patients with solid tumors treated with single-agent TRX518, a GITR agonist, no responses were observed but subsequent pre-clinical work showed the addition of PD-1 blockade overcame anti-GITR resistance and induced tumor regression,^[@bibr138-1758835920937902]^ and thus providing a rationale for combining with an ICI ([Table 3](#table3-1758835920937902){ref-type="table"}). Early phase studies of GITR agents such as MK-1248 and MK-4166 have reported responses when combined a PD-1 inhibitor.^[@bibr139-1758835920937902]^

### Co-inhibitory or other immune checkpoints {#section23-1758835920937902}

The effectiveness of two ICIs in advanced NSCLC was shown in CHECKMATE 227 with ipilimumab plus nivolumab resulting in an improvement in PFS in patients with a high TMB^[@bibr23-1758835920937902]^ and prolonged OS in patients regardless of PD-L1 status.^[@bibr140-1758835920937902]^ In contrast, the combination durvalumab and tremelimumab in the MYSTIC study did not meet the primary endpoint for OS *versus* chemotherapy.^[@bibr24-1758835920937902]^

Other checkpoints have also been studied. Inhibition of LAG-3 restores T effector cells activity and reduces the activity regulatory T cells, enhancing the anti-tumor activity of PD-1 inhibition.^[@bibr141-1758835920937902]^ The combination of anti-PD-1 and anti-LAG-3 therapy has been reported to increase anti-tumor activity compared with anti-PD-1 alone in melanoma patients who have progressed on anti-PD-1 therapy.^[@bibr142-1758835920937902]^ In a phase I/II study of pre-treated patients with advanced solid tumors treated with a LAG-3 inhibitor (LAG-525) and PD-1 inhibitor (PDR001), durable responses were observed in three out of eight patients with mesothelioma and two out of five patients with triple negative breast cancer, but no responses were seen in patients with NSCLC.^[@bibr143-1758835920937902]^ In a phase I study, NSCLC patients with prior anti-PD-1/PD-L1 treatment received TSR-022 (TIM-3 inhibitor) in combination with TSR-042 (PD-1 inhibitor), with a response rate of 13% reported.^[@bibr144-1758835920937902]^

Such ICI combinations in patients who have progressed on ICI monotherapy may help to target the changing TME seen during treatment with anti-PD1 therapy with on treatment biopsy assessment showing upregulation of related checkpoint genes PDCD1 (PD-1), CD284 (PD-L1), CTLA-4, and LAG3 among others.^[@bibr145-1758835920937902]^ An adaptive approach may be required with alternating combinations utilized dependent on biopsy assessment in view of these dynamic changes.

Future approaches and conclusion {#section24-1758835920937902}
================================

ICI therapy is associated with durable responses in a minority of patients with many displaying primary resistance, while secondary resistance to therapy subsequently occurs in a significant proportion. Here we have reviewed some of the main drivers behind such resistance and potential therapeutic strategies to overcome them.

Currently, multiple studies examining the combination of immunotherapeutic agents with cytotoxic chemotherapy, radiation, or molecular targeted agents are underway, with the aim of reducing resistance and providing long-lasting disease control. In addition, combining immunotherapeutic agents with ICI is an area of intense research, with agents targeting the IFN/JAK escape pathway, immunosuppressive immune cells and molecules, co-inhibitory/immune checkpoints, and co-stimulatory signals ([Table 3](#table3-1758835920937902){ref-type="table"}). With the rapid pace of immunotherapy drug development and the burgeoning number and often duplicate combination studies,^[@bibr146-1758835920937902]^ to increase the chances of success, rationally designed clinical trials of combination agents becomes imperative and should be based on robust pre-clinical data, together with the use of pharmacodynamic biomarkers and novel innovative endpoints.^[@bibr147-1758835920937902]^

It should be noted that much of our current knowledge on resistance mechanisms and its biomarkers is derived from melanoma studies, and the ability to apply this in the NSCLC setting is uncertain with further studies specific to lung cancer required. Such studies will ideally incorporate a standardized definition of primary and secondary ICI resistance as suggested in this review to allow accurate categorization of response and they will need to overcome the problem of sample accessibility to allow longitudinal tumor assessments in order to accurately depict on treatment changes underlying resistance.

To date, precision medicine has been applied successfully in oncogene-driven NSCLC.^[@bibr148-1758835920937902]^ To enable personalized cancer immunotherapy, advances in immune-diagnostics and biomarker development are ongoing together with major efforts to increase our understanding of the mechanisms of response and resistance to ICIs.^[@bibr64-1758835920937902],[@bibr80-1758835920937902],[@bibr149-1758835920937902][@bibr150-1758835920937902]--[@bibr151-1758835920937902]^

**Conflict of interest statement:** RAS has received honoraria from Astra-Zeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan; and research funding from Astra-Zeneca and Boehringer Ingelheim. RJW reports no conflict of interest.

**Funding:** The authors received no financial support for the research, authorship, and/or publication of this article.
